Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim Dokter1, Ruud Ubink1, Miranda van der Lee1, Monique van der Vleuten1, Tanja van Achterberg1, Danielle Jacobs1, Eline Loosveld1, Diets van den Dobbelsteen1, David Egging1, Ellen Mattaar1, Patrick Groothuis1, Patrick Beusker2, Ruud Coumans2, Ronald Egersma2, Wiro Menge2, John Joosten2, Henri Spijker2, Tijn Huijbregts2, Vincent de Groot2, Michel Eppink3, Guy de Roo3, Gijs Verheijden3, and Marco Timmers4

Abstract
A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation antibody–drug conjugates (ADC). A leading ADC originating from that platform is SYD983, a HER2-targeting ADC based on trastuzumab. HER2-binding, antibody-dependent cell-mediated cytotoxicity and HER2-mediated internalization are similar for SYD983 as compared with trastuzumab. HER2-expressing cells in vitro are very potently killed by SYD983, but SYD983 is inactive in cells that do not express HER2. SYD983 dose dependently reduces tumor growth in a BT-474 mouse xenograft in vivo. The ADC is stable in human and cynomolgus monkey plasma in vitro but shows relatively poor stability in mouse plasma due to mouse-specific carboxylesterase. SYD983 could be dosed up to 30 mg/kg in cynomolgus monkeys with high exposure, excellent stability in blood, and without severe toxic effects. The monkey safety study showed no SYD983-induced thrombocytopenia and no induction of peripheral sensory neuropathy, both commonly observed in trials and studies with ADCs based on tubulin inhibitors. Finally, to improve homogeneity, SYD983 was further purified by hydrophobic interaction chromatography resulting in an ADC (designated SYD985) predominantly containing DAR2 and DAR4 species. SYD985 showed high antitumor activity in two patient-derived xenograft models of HER2-positive metastatic breast cancers. In conclusion, the data obtained indicate great potential for this new HER2-targeting ADC to become an effective drug for patients with HER2-positive cancers with a favorable safety profile. More generally, this new-generation duocarmycin-based linker-drug technology could be used with other mAbs to serve more indications in oncology. Mol Cancer Ther; 13(11); 2618–29. ©2014 AACR.

Introduction
Antibody–drug conjugates (ADC) are mAbs that are chemically linked to cytotoxic agents. Although the concept exists for decades, only recent advances in linker, drug, and antibody technology have turned ADCs into valuable therapeutic agents as illustrated by the recent approvals of brentuximab-vedotin (Adcetris) and ado-trastuzumab emtansine (T-DM1, marketed as Kadcyla). In addition to these approved ADCs, more than 30 other ADCs are currently in clinical trials of which the majority are based on linker-drugs (LD) that are similar to those used in brentuximab-vedotin and T-DM1 (1, 2). Like many ADCs in development, both brentuximab-vedotin and T-DM1 carry tubulin binders (an auristatin and a maytansinoid, respectively) that inhibit tubulin polymerization and cause cell-cycle arrest and apoptosis of the targeted cell. Linkers are either cleavable linkers, for example, peptide linkers (such as the di-peptide valine-citrulline used in brentuximab-vedotin) or non-cleavable linkers, for example, amide or thioether linkers (as used in T-DM1) that depend on complete degradation of the mAb in the lysosome and subsequent release of the cytotoxic agent. Linkers are either cleavable linkers, for example, peptide linkers (such as the di-peptide valine-citrulline used in brentuximab-vedotin) or non-cleavable linkers, for example, amide or thioether linkers (as used in T-DM1) that depend on complete degradation of the mAb in the lysosome and subsequent release of the cytotoxic agent. Although the marketed ADCs have an improved therapeutic index (TI) compared with classical nontargeted chemotherapeutic agents, there is still room for improvement. Brentuximab-vedotin, for example, reaches its MTD in human patients at 2.4 mg/kg every 3 weeks, which is determined by induction of peripheral sensory
neuropathy, neutopenia, and thrombocytopenia (3–5). Similarly, the MTD of T-DM1 is 3.6 mg/kg every 3 weeks, which is also driven by unacceptable thrombocytopenia and hepatotoxicity at higher dosages, and is accompanied by peripheral sensory neuropathy as well (6–9).

A new-generation platform of LDs has been developed on the basis of chemically synthesized duocarmycins which are DNA-alkylating cytotoxic drugs (10, 11) that induce cell death in both dividing and nondividing cells. The aim is to improve the currently used LDs and increase the TI that can be obtained with ADCs based on these new LDs as compared with that of the earlier generation ADCs. To assess the value of this new LD technology, ADCs were prepared on the basis of the mAb trastuzumab to target HER2-positive tumors. Trastuzumab was chosen for two main reasons. First, the biology of trastuzumab and HER2 is well known (12) and HER2 is a clinically validated target. Second, the safety profile of T-DM1 clearly indicates that there is room for a HER2-targeting ADC with an improved TI (6–9).

A set of trastuzumab-based ADCs were prepared by chemical linkage of different LDs to the thiol groups of cysteines generated by random reduction of interchain disulfides on the mAb, using thiol-maleimide chemistry. The profile of lead candidate SYD983 is presented in this paper. We showed that SYD983 combines a high antitumor activity with an impressive safety profile indicating its superior preclinical TI compared with existing ADCs.

**Materials and Methods**

**Antibodies and ADCs**

Vc-seco-DUBA 1, seco-DUBA 2, and SYD983 were prepared essentially as described previously (13, 14) and further detailed in the Supplement. Trastuzumab was expressed using Chinese Hamster Ovary cells and purified to homogeneity. IgG1 control antibody infliximab was from MSD. Nonbinding control ADC was vc-seco-DUBA 1 coupled to rituximab (Roche) using a similar method as for conjugating trastuzumab, resulting in a comparable DAR (see Supplementary Materials and Methods).

**Cell lines and reagents**

Human tumor cell lines BT-474, SK-BR-3, SK-OV-3, NCI-H520, and SW-620 were obtained from and characterized by the American Type Culture Collection. No further cell-line authentication was conducted. SW-620 and NCI-H520 cells were cultured in RPMI-1640 media (Lonza) supplemented with 10% v/v FBS, heat inactivated (Hi; Gibco-Life Technologies) at 37°C in a humidified incubator containing 5% CO2, SK-BR-3 and SK-OV-3 were maintained in McCoy's-5A medium (Lonza) containing 10% v/v FBS HI, and BT-474 cells in RPMI-1640 containing 2 mol/L l-glutamine (Lonza) supplemented with 10% FBS (Lonza). Quantification of cell surface HER2 expression was done using the DAKO Qifi kit (DAKO), according to the manufacturer’s protocol.

**In vitro characterization of SYD983**

Cells in complete growth medium were plated in 96-well plates (90 μL/well) and incubated at 37°C, 5% CO2 at the following cell densities: 6,500 SK-BR-3, 10,000 BT-474, 2,000 SK-OV-3, 4,000 SW-620 and 5,000 NCI-H520 cells per well. After an overnight incubation, 10 μL of mAb, seco-DUBA 2 and/or ADC were added. Cell viability in serial dilutions was assessed after 144 hours (or indicated otherwise) using the CellTiter-Glo luminescent assay kit from Promega Corporation according to the manufacturer’s instructions. Metabolic activity of BT-474 cells was measured with an ATP-Lite assay (PerkinElmer). Cytotoxicity was measured after 96 hours by detection of a protease, which was released by membrane-compromised cells (Cytotox-Glo cytotoxicity assay; Promega). Internalization studies are detailed in the Supplement. Antibody-dependent cell-mediated cytotoxicity (ADCC) assays were conducted essentially as described (15) and detailed in the Supplementary Materials and Methods.

**Cell line and patient-derived xenograft studies**

Studies were approved by the local animal care and use committees according to established guidelines. The BT474 model was performed at Oncodesign (Dijon, France). Tumors were induced subcutaneously by injecting 2 × 106 BT-474 cells in 200 μL of RPMI-1640 containing Matrigel (50:50; v/v; BD Biosciences) into the right flank of female Balb/c nu/nu mice. BT-474 tumor cell implantation was performed 48 hours after a whole body irradiation with a γ-source (2 Gy, 60Co, BioMap). Mice were randomized into experimental groups when tumors reached a size between 350 to 400 mm3, and dosing initiated. The mice were dosed intravenously (5–10 mL/kg) in the tail vein with the respective ADCs in vehicle (80 mg/mL trehalose,10 mmol/L histidine, 0.01% polysorbate-20, pH 6) or with vehicle alone.

Two metastatic HER2 IHC 3+ positive breast cancer patient-derived xenograft (PDX) studies were conducted at Oncotest (Freiburg, Germany). MAXF1322 mammary tumor was a metastasis from a brain tumor of a 49-year-old female patient, and MAXF1162 mammary tumor was a primary tumor in the breast of a 55-year-old female patient. HER2 IHC was performed by using formalin-fixed paraffin-embedded tumor xenograft samples and a polyclonal rabbit anti-human HER2 (DAKO Cat# A0485) antibody and detected by a biotinylated goat anti-rabbit IgG (JacksonImmuno research, Cat# 111-065-04) and a Biozol (Cat # VEC-PK-4000) ABC kit. Staining was evaluated semiquantitatively, using a Zeiss Axiosvert 35 microscope. Staining was interpreted as immunoreactivity, based on the proportion of positively-stained cells and on the signal intensity, according to the established guidelines. A known HER2-positive (IHC 3+) and HER2-negative (IHC 0) control tumor slide was included in every HER2 staining procedure (See Supplementary Fig. S5) to control for specificity.

PDX experiments were conducted as described (16). Mice (n = 8–10 per group) were dosed once intravenously.
In vitro profile of SYD983

Internalization of Alexa488-labeled SYD983 into HER2-positive breast SK-BR-3 cells was compared with that of Alexa488-labeled trastuzumab. Internalization of SYD983 at 37°C is time dependent reaching maximal levels of approximately 60% at 8 hours, similar to that of the naked Ab (Fig. 2A). As a control, SYD983 was not significantly internalized at 4°C (Fig. 2A). Binding affinity (KD,observed) for SYD983 and trastuzumab was 1.1 E-9M and 1.2 E-9M, respectively, indicating that SYD983 conjugation did not affect HER2-binding affinity. Also the ability of SYD983 to induce ADCC was not affected by conjugation (Fig. 2B). It is concluded that conjugation of vc-seco-DUBA 1 to trastuzumab does not alter important characteristics of the mAb, like has been described for T-DM1 (20).

Next, some aspects of SYD983 were studied that relate to the duocarmycin payload. A set of five human tumor cell lines were selected on the basis of their published HER2 status: breast carcinomas SK-BR-3 and BT-474 (both HER2 3+), ovarian carcinoma SK-OV3 (HER2 2+), and metastatic colon carcinoma SW-620 and lung adenocarcinoma NCI-H520 (both HER2 negative). The HER2 status of these cell lines was confirmed by quantifying HER2 levels using Qfitkit, indicating 815,000 (SK-BR-3), 910,000 (BT-474), 600,000 (SK-OV3), 150 (NCI-H520), and 1100 (SW-620) HER2 molecules per cell which is in line with previous publications (21, 22). First these cell lines were studied for their sensitivity to sec-DUBA 2 (Fig. 1), which is the active toxin released after intracellular processing of SYD983. All five cell lines were highly sensitive to sec-DUBA 2 with a potency between 0.8 and 4.3 x 10^-10M in all cell lines tested (Fig. 2C). Incubation with a dose range of SYD983 showed that potencies and efficacies for SYD983 were in line with HER2 expression; 1.42 ± 0.06 E-10M (98% cell killing), 8.07 ± 0.06 E-10M (98% cell killing), 7.50 ± 0.02 E-10M (78% cell killing) for SK-BR-3, BT-474, and SK-OV3, respectively. An enormous reduction in potency was observed in the cell lines that are HER2 negative (> 5 E-8M) for SW-620 and NCI-H520 (Fig. 2D). The resulting 1,000-fold window of potencies for SYD983 in HER2-positive versus HER2-negative cell lines indicates that induction of cytotoxicity in HER2-positive cell lines is mediated through HER2. To further study the mechanism of action, the number of viable SK-BR-3 cells was compared after incubation for 4 days with either SYD983, a nonbinding control ADC with the same payload and average DAR, or trastuzumab. Trastuzumab lowered the number of viable cells but not to the level at the start of the experiment at day 0 (Fig. 2E), suggesting that trastuzumab induced partial inhibition of cell proliferation. In contrast, SYD983 reduced the number of viable cells below the initial number at day 0, suggesting induction of cytotoxicity. The nonbinding ADC showed no effect on cell viability. Because only SYD983, and neither trastuzumab nor the nonbinding control ADC, dose dependently induced extracellular release of an intracellular protease (Fig. 2F), we conclude that SYD983, in contrast with trastuzumab, induces cytotoxicity, which is HER2 mediated.
**In vivo antitumor activity**

The *in vivo* antitumor activity of SYD983 was evaluated in a BT-474 mouse xenograft model. Trastuzumab dosed once at 5 mg/kg showed moderate antitumor activity in this model (Fig. 3A). SYD983 dose dependently reduced tumor growth. At 5 mg/kg, the tumor volume was significantly decreased from day 34 onwards (log-transformed data; two-way ANOVA, multiple comparisons). At 1 mg/kg, SYD983 showed equal antitumor activity as 5 mg/kg trastuzumab. This improved antitumor activity of SYD983 is due to HER2 targeting of the duocarmycin to the tumor because the combination of 15 mg/kg trastuzumab and the free toxin Seco Drug 2 equimolar to what would be present in a 15 mg/kg SYD983 group, did not improve the antitumor activity compared with 15 mg/kg trastuzumab alone. Both treatments were statistically significant from day 33 onwards (Fig. 3B). Next, it was studied whether antitumor activity in the BT-474 xenograft model was dependent on peak levels of SYD983 ($C_{\text{max}}$-driven) or on the AUC driven of the total exposure to SYD983. To mimic a situation of different $C_{\text{max}}$ levels, but rather similar AUCs, mice carrying BT-474 tumors were treated either once with 5 mg/kg versus five times with 1 mg/kg SYD983 once every day. Both of these treatments resulted in similar antitumor activity, indicating that the AUC drives efficacy (Fig. 3C). As a control, 1 mg/kg SYD983 dosed once was indeed less effective. In a multiple dose experiment, it was confirmed that the antitumor activity of SYD983 in this...
BT-474 xenograft model was dependent on targeting of the toxin to the target, because a nonbinding control ADC with the same payload as SYD983 showed no antitumor activity (Fig. 3D). These data show that SYD983 exhibits potent HER2-mediated antitumor activity in vivo.

Plasma stability and kinetics
Ve-seco-DUBA was predicted to be sensitive to certain esterase activity that could hydrolyze the carbamate bond connecting the alkylating moiety of the duocarmycin to the self-elimination module (Fig. 1) and thereby liberating...
the toxin. Indeed, the stability of SYD983 in mouse plasma is poor (Fig. 4A and Supplementary Table S1) and solely due to plasma expression of mouse-specific carboxylesterase CES1c (23, 24), because SYD983 is stable in plasma prepared from CES1c knockout mice (Fig. 4B). Thus, it cannot be ruled that some antitumor activity of SYD983 in mice is induced by the early release of payload in the vicinity of the tumor by mouse-specific CES1c. Stability of SYD983 in plasma from cynomolgus monkeys and humans is good and in line with the absence of carboxylesterase activity in plasma from those species (23).

In vivo plasma kinetics were studied in healthy Balb/c mice and in tumor-bearing nu/nu mice. Total antibody (TAb) levels in healthy Balb/c mice are in line with previously reported stability for trastuzumab in mice (25), with a terminal half life of 309 hours and a clearance of 0.34 mL/hour/kg at 1 mg/kg SYD983 (Fig. 4C and Supplementary Table S2). This indicates that the conjugation has no clear effect on TAb PK. In tumor-bearing mice, the clearance was -fold higher (2.13 mL/hour/kg), in line with target-mediated drug disposition (Fig. 4D and Supplementary Table S3). In contrast, ADC exposure rapidly declines resulting in much higher clearance values, being similar for healthy (14.3 mL/hour/kg) and tumor-bearing mice (13.8 mL/hour/kg) at 1 mg/kg. This rapid decline is in line with the plasma stability data and probably caused by CES1c esterase activity and much more pronounced than the target-mediated clearance in tumor-bearing mice.

In monkey, TAb PK showed slightly higher clearance (e. g., 0.58 ± 0.03 mL/hour/kg at 3 mg/kg) compared with previously reported data for trastuzumab (25–27), but also...
showed nonlinear PK at the lower dosages (Fig. 4E). Distinct from the mouse data, ADC concentrations hardly decline resulting in clearance values (e.g., 0.64/C6 0.03 mL/hour/kg) that are only slightly higher than TAb clearance values (Supplementary Tables S4 and S5).

Safety and therapeutic index

The tissue-specific expression of HER2 in cynomolgus monkey closely resembles that of humans (28), and trastuzumab does bind to cynomolgus HER2 with a comparable affinity to human HER2. The plasma exposure of SYD983 in cynomolgus monkeys is high and plasma stability of SYD983 in cynomolgus and human plasma is similar. Although we cannot rule out that processing of the LD might be different in monkey versus human, we do consider cynomolgus monkeys to be the most relevant species for SYD983 nonclinical safety studies.

SYD983 was very well tolerated in cynomolgus monkeys up to two dosages of 30 mg/kg 3.5 weeks apart. Exposure of SYD983 was high and in line with the dosing regimen (Fig. 4E). Effects observed were all mild and transient (Table 1). The highest non-severely toxic dose (HNSTD) was estimated to be /C21 30 mg/kg. Most interestingly, no hepatotoxicity, thrombocytopenia, and no signs of peripheral sensory neuropathy were observed which was confirmed by pathology assessment. The latter two observations are of special interest because they may

Figure 4. In vitro and in vivo kinetics of SYD983 in different species. A and B, ADC concentration after 96-hour incubation of 100 μg/mL SYD983 at 37°C in human, monkey, and mouse plasma (A) or plasma from mouse carboxylesterase 1c (CES1c) knockout mice versus wild-type mice (B). C–E, time concentration curves of TAb or ADC concentration (n = 3, ± SEM) after single-dose intravenous administration of 0.2, 1, or 5 mg/kg SYD983 to healthy Balb/c mice (C), 1 or 5 mg/kg SYD983 to tumor-bearing Balb/c nu/nu mice (D), or 1,3,10, or 30 mg/kg SYD983 in cynomolgus monkeys (E). The concentration of intact ADC or TAb was quantified by sandwich ELISA.
be important potential differentiators to other LD technologies in general and to T-DM1 in particular.

The AUC at the HNSTD (30 mg/kg/cycle) in cynomolgus monkeys is 100,051 µg/hour/mL, which is a factor of 300 higher than the exposure of 333 µg/hour/mL in mice at the effective dose of 5 mg/kg. These data indicate a large TI of SYD983 in the preclinical setting, suggesting sufficient window to reach antitumor activity at a dose with an acceptable safety profile in humans. Because the TI was obtained in two different species, one of which is the mouse where SYD983 has a poor PK, translatability of these data to human will only be proven in clinical trials.

**HIC purification of SYD983; preparation of SYD985**

SYD983 is a heterogeneous mixture of nonconjugated Abs and conjugated Abs with a DAR of 2, 4, 6, and 8 (Supplementary Fig. S1A). For further (pre-)clinical development, we preferred an ADC that is more homogeneous and preferably does not contain naked Ab, to increase the DAR and reduce competition of naked Ab on the tumor antigen and thereby increase its potential antitumor activity. Hydrophobic interaction chromatography (HIC)-based purification was used to deliver a well-defined ADC consisting predominantly of DAR2 and DAR4 species (Supplementary Fig. S1B). This more homogeneous ADC was designated SYD985. SYD985 has an average DAR of 2.7 versus 2.0 for SYD983. As can be expected on the basis of the increased DAR in SYD985, its potency to kill HER2-expressing SK-BR-3 cells in vitro is indeed increased (2-fold) compared with SYD983 (Supplementary Fig. S2).

**Antitumor activity in a breast cancer patient–derived xenograft**

Finally, efficacy of SYD985 was studied in two breast cancer PDX models named MAXF1322 and MAXF1162. Both of these tumors are HER2 3+ cancer PDX models named MAXF1322 and MAXF1162. It was shown that these PDX models do not respond to a high dose of trastuzumab, dosed four times at a 4-day interval (Fig. 5C and D). In both tumor models, SYD985 dose dependently reduced tumor growth after a single compound administration. This effect was dependent on HER2 expression on the tumors because the antitumor activity of SYD985 was significantly better than that of the nonbinding isotype control ADC (Fig. 5E and F). Thus, SYD985 induces strong HER2-mediated antitumor activity in these HER2 positive-breast cancer PDX models, illustrating its potential clinical benefit in this patient group.

**Discussion**

Many of the ADCs currently in clinical and preclinical development are based on LDs that are present in either brentuximab-vedotin (auristatins) or T-DM1 (maytansinoids; refs. 1, 2). The TI of the current ADCs on the market is limited and does indicate the need for new-generation LDs with greater benefit/safety ratios. We have developed a LD technology based on the highly potent cytotoxic duocarmycin class of compounds that is bound in an inactive form to a cleavable linker that is highly stable in human plasma but sensitive to proteases in the tumor. We have evaluated this technology by profiling a HER2-targeting ADC, SYD983, based on the mAb trastuzumab and vc-seco-DUBA, one of our new generation LDs.

SYD983 was selected as the best performing ADC from a series of related ADCs profiled in a Lead Optimization program. Because conjugation occurs randomly on cysteine residues, SYD983 has a theoretical DAR distribution encompassing DAR0, 2, 4, 6, and 8 species. Higher DAR species (DAR6 and DAR8) are generally less stable, clear more rapidly, more easily exchange LD to thiol-reactive constituents like albumin in plasma, and therefore have a relative large contribution to toxicity (29). The DAR0 species, which is trastuzumab in the case of SYD983, do not contribute to toxin-mediated antitumor activity and even will compete for antigen-binding sites, reducing the potential antitumor activity of the ADC. Therefore, an ADC with a more defined DAR distribution containing DAR2 and DAR4 species only is preferred. We have used HIC to purify SYD983 and thereby remove DAR0, DAR6, and DAR8 species. The resulting SYD983 predominantly

---

**Table 1. Summary of findings in dose range–finding toxicity and PK study in cynomolgus monkey**

| Parameter/organ system          | Effect                                                                 |
|---------------------------------|------------------------------------------------------------------------|
| Body weight                     | Maximum transient body weight loss: 8.7% (2nd cycle)                   |
| White blood cell populations    | Mild transient decreases at ≥ 10 mg/kg/cycle                            |
| Red blood cell parameters       | Transient decrease followed by rebound in reticulocytes at ≥ 10 mg/kg/cycle |
| Thrombocytes                    | No reduction below 95% confidence intervals of population predose values (NOEL: ≥ 30 mg/kg/cycle) |
| Liver                           | No effect on transaminases, albumin, bilirubin, and histopathology (NOEL: ≥ 30 mg/kg/cycle) |
| Peripheral neuropathy           | Mild effects in line with target expression                             |
| Ovaries                         | No effects on behavior and histopathology (NOEL: ≥ 30 mg/kg/cycle)     |
| Skin                            | Hyperpigmentation at dosages ≥ 10 mg/kg/cycle. Reversible facial swelling in 1 animal at 10 mg/kg/cycle. |
contains DAR2 and DAR4 species with a mean DAR of 2.7. SYD985 behaves as a potent antitumorigenic ADC in relevant PDXs.

In line with what has been observed for other ADCs and especially T-DM1 (30), our in vitro studies support a mechanism of action in which SYD983 binds to HER2, internalizes, and releases its cytotoxic payload. We showed that the potent in vitro cell cytotoxicity does translate into effective antitumor activity in vivo in xenografts, including in PDX models that represent the current target cancer population for T-DM1 treatment, for example, HER2-positive metastatic breast cancer patients.

SYD983 has a poor stability in mouse plasma which induces poor exposure of intact ADC in mice. In contrast, stability of SYD983 in cynomolgus monkey plasma is very high resulting in very stable PK in cynomolgus monkeys after dosing in vivo. Thus for vc-seco-DUBA, in vitro plasma stability does predict for stability and PK in vivo. It is therefore expected that the high stability of SYD983 in human plasma will lead to high exposure of intact ADC in patients. The poor stability of SYD983 in mouse plasma is
solely due to CES1c activity because SYD983 is very stable in plasma from CES1c knockout mice. The poor exposure in terms of AUC of SYD983 in mice is very likely affecting its antitumor activity in mice. As for T-DM1 (31), also antitumor activity of SYD983 is driven by the AUC rather than C_{max}. Thus, the antitumor activity of SYD983 and SYD985 will most likely increase once the AUC of intact ADC will increase. It cannot be ruled out though some antitumor activity is induced by the release of the payload in the vicinity of the tumor by mouse-specific CES1c. Clinical studies with SYD985 will demonstrate whether indeed this is the case. In addition, efficacy studies in CES1c knockout mice might importantly contribute to better understanding the PK/PD relationship.

Data from safety studies in cynomolgus monkey were used to compare the SYD983 profile with T-DM1 (28) as the main comparator competitor drug. In clinical practice, the main adverse effects of T-DM1 are induction of thrombocytopenia and of peripheral neuropathy, which is a major, possibly irreversible, disabling adverse effect for patients (6–9). Platelet counts did decrease approximately 30% in cynomolgus monkeys treated with T-DM1 at 30 mg/kg/cycle (28). Thrombocytopenia does limit the maximal human dose of T-DM1 to 3.6 mg/kg every 3 weeks. In cynomolgus monkey, SYD983 did not show any signs of hepatotoxicity or peripheral neuropathy, by visual examination of the animals and pathologic examination of the spinal cord. In addition, no effects on thrombocytes were noted. Clinical studies should prove whether these potential differentiators to T-DM1 will lead to benefits in terms of absence of neuropathy and/or in terms of the ability to dose SYD983 higher leading to potentially better clinical outcome. For both T-DM1 and brentuximab-vedotin, dose-limiting-toxicity in cynomolgus monkeys is driven by toxic effects in the hematopoietic system and thought to be mediated through plasma levels of the free toxins (28, 32), which are DM1 and MMAE, respectively. The first signs of toxicity of SYD983 in cynomolgus monkeys are hyperpigmentation in the skin which is thought to be mediated through HER2-positive melanocytes (33). Thus, in contrast with T-DM1 and brentuximab-vedotin, the first signs of toxicity for SYD983 seem target related rather than related to free toxin levels. Future vc-seco-DUBA-based ADC programs directed toward other antigens will show whether this potential benefit for the vc-seco-DUBA LD technology sustains and does translate into humans.

In addition to the proposed mechanism of action where the ADC is internalized and toxin is released within the lysosome by proteases like cathepsins, vc-seco-DUBA may be cleaved in the tumor by extracellularly available proteases, thereby releasing the cytotoxic payload outside the target cells and inducing a bystander effect. Proteases such as cathepsins, especially cathepsin B and L, are highly expressed in a wide range of tumors, including breast cancer tumors, where they have been implicated in tumorigenesis (34) and associated with a poor clinical outcome (34–37). It is tempting to speculate that the cleavable linker in SYD985 will indeed allow a significant bystander effect and perhaps enable successful treatment of tumors in which not all tumor cells express high levels of HER2. Further experiments are ongoing to test that hypothesis.

The duocarmycin class of compounds has been explored by several others for application in ADCs (38–40). The anti-CD70 ADC MDX-1203 is the only duocarmycin-based ADC; however, that has been taken into the clinic. The main difference between the linker-duocarmycin used in MDX-1203 versus SYD983 is that in MDX-1203, the linker is connected to the DNA binder moiety, which necessitates the use of an additional cleavable protecting group on the hydroxyl group of the DNA alkylator to stabilize the LD, whereas the linker in SYD983 is directly coupled to the hydroxyl group of the DNA alkylator, thereby eliminating the need for a second promoiety. The double prodrug approach as applied in MDX-120-3 therefore requires two cleavage steps in the tumor cell to release the active toxin, which potentially increases the risk of insufficient activation.

We conclude that SYD983 combines a high antitumor activity with an impressive safety profile. The superior preclinical TI compared with established LD technologies formed the basis for the decision to progress our HER2-targeting ADC toward clinical studies. This will be done with SYD983, a HIC-purified form of SYD983 that is more homogeneous and predominantly contains DAR2 and DAR4 species. SYD985 is the most progressed ADC based on a new duocarmycin-based LD technology platform. When taken more generally, the data presented in this paper indicate that vc-seco-DUBA, a new-generation LD as used in SYD983/SYD985, might be used on many other mAbs to create effective and safe ADCs for many more indications in oncology.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed by the authors.

**Authors' Contributions**

Conception and design: W. H. Dokter, R. Ubink, M. van der Lee, P. Groothuis, P. Beusker, V. de Groot, M. Timmers

Development of methodology: R. Ubink, M. van der Lee, T. van Achterberg, E. Loosveld, D. van den Dobbelsteen, D. Egging, E. Mattaar, P. Beusker, R. Coumans, R. Eversma, W. Menges, J. Joosten, H. Spijker, T. Huijbregts, V. de Groot, M. Eppink, G. de Roo

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. van der Lee, T. van Achterberg, E. Loosveld, E. Mattaar, P. Groothuis

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W. H. Dokter, R. Ubink, M. van der Lee, M. van der Vleuten, T. van Achterberg, D. Jacobs, E. Loosveld, D. van den Dobbelsteen, D. Egging, P. Groothuis, P. Beusker

Writing, review, and/or revision of the manuscript: W. H. Dokter, R. Ubink, M. van der Lee, M. van der Vleuten, T. van Achterberg, D. Jacobs, E. Loosveld, D. Egging, P. Groothuis, P. Beusker, M. Eppink, G. Verheijden, M. Timmers

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Ubink, M. van der Lee, M. van der Vleuten, T. van Achterberg, D. Jacobs

Study supervision: W. H. Dokter, R. Ubink, M. van der Lee, M. van der Vleuten, D. van den Dobbelsteen, P. Groothuis, G. Verheijden

**Acknowledgments**

The authors thank Prof. T. Hagemann (London, UK) for providing access to plasma of CES1c knockout mice.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 17, 2014; revised July 17, 2014; accepted August 13, 2014; published OnlineFirst September 4, 2014.

REFERENCES

1. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248–62.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann Rev Med 2013;64:15–29.
3. Gopal AK, Ramchandren R, O’Connor OA, Berman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin in Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120:560–8.
4. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183–9.
5. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Iliidine T, et al. Brentuximab-vedotin (SGM-39) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–6.
6. Burnis Halil, Hugo RS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody-drug conjugate brentuximab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398–405.
7. Krop IE, Loffrussolo P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A Phase II study of trastuzumab-entansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:1–9.
8. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab-Entansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783–91.
9. Hurvitz SA, Dirik L, Kocsics J, Blanchi GV, Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab vups docolaxet in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2013;31:1157–63.
10. Martin DG, Chidester CG, Duchamp DJ, Milsak SA. Structure of CC-1065 (NSC 298223), a new antitumor antibiotic. J Antibiotics 1980;33:902–1065 (NSC 298223), a new antitumor antibiotic. J Antibiotics
11. Hogler DL, Johnson DS. CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci USA 1995;92:3642–9.
12. Hudis CA. Trastuzumab. N Engl J Med 2000;343:37–51.
13. Beerse PH, Comans RGE, Elgersma RC, Menge WMPB, Joosten JAF, Spijker HJ, et al. Novel CC-1065 analogs and their conjugates. Int Patent Publ WO 2010/062171.
14. Beerse PH, Comans RGE, Elgersma RC, Menge WMPB, Joosten JAF, Spijker HJ, et al. Novel conjugates of CC-1065 analogs and bifunctional linkers. Int Patent Publ WO 2011/133039.
15. Idusogie EE, Presta LG, Gazanno-Santoro H, Topal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000;164:4178–84.
16. Smith V, Wirth GJ, Fiebig HH, Burger AM. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genom Proteom 2008;5:263–74.
17. Cristofanilli M, Bryan WJ, Miller LL, Chang AYC, Gradishar WJ, Kufe DW, et al. Phase II study of adozelesin in untreated metastatic breast cancer, Anti-Cancer Drugs 1998;9:779–82.
18. Pavia B, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin’s lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000;46:167–71.
19. Markovic SN, Surman VJ, Yukov AM, Fitch TR, Hillman DW, Adjei AA, et al. Phase II trial of KOS198 in patients with advanced malignant melanoma. Am J Clin Oncol 2002;25:308–12.
20. Juntilla TL, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanism of action of trastuzumab and efficiently inhibits growth of lapatinib-insensitive breast cancer. Breast Cancer Res Treat 2011;128:347–56.
21. Nagy P, Friedlander E, Tanner M, Kapanen AJ, Carraway KL, Isola J, et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473–82.
22. Nordstrom JL, Gotlibov S, Zhang W, Yang Y, Huang L, Burke S, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res 2011;13:R123.
23. Li B, Sedlacek M, Manchuli I, Boopathy R, Duyan SE, Masson P, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005;70:1673–84.
24. Duyan SE, Koentgen F, Williams GR, Timperley CM, Schopfer LM, Cerasoli DM, et al. Production of ES1 plasma carboxylesterase knock-out mice for toxicity studies. Chem Res Toxicol 2011;24:1891–8.
25. Zhang N, Liu L, Dumitru CD, Houston Cummings NG, Cukan M, Jiang Y, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 2011;3:289–98.
26. Dittaye M, Masubuchi N, Ito T, Yabe Y, Karbe T, Aoki T, et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011;26:423–30.
27. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. What have we learned? mAbs 2011;3:61–6.
28. Poon KA, Flagella K, Beyer J, Tibbits J, Kaur S, Saad O, et al. Preclinical safety profile of trastuzumab-entansine (T-DM1): mechanism of action of an antibody-drug conjugate retained with improved tolerability. Toxicol Appl Pharmacol 2013;273:298–313.
29. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063–70.
30. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotox drug conjugate. Cancer Res 2008;68:9280–90.
31. Jumbe NL, Xin Y, Leijold CD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 2010;37:221–42.
32. FDA report Application number 125399Orig1s000, Center for Drug Evaluation and Research, Pharmacology Review brentuximab vedotin (Adcetris), 2011.
33. Stoie C, Stove V, Derycke L, van Marck V, Marel M, Bracke M. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol 2003;121:802–12.
34. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764–75.
35. Szapadernia AM, Frankfater A. An intracellular form of cathepin B contributes to invasiveness in cancer. Cancer Res 2001;61:3493–500.
36. Roshty S, Sloane BF, Moin K. Pericellular cathepin B and malignant progression. Cancer and Metastasis Reviews 2003;22:71–86.
37. Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 2003;70:263–76.
38. Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG, Denny WA, et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J Med Chem 2005;48:1344–58.

39. Jeffrey SC, Nguyen MT, Moser RF, Meyer DL, Miyamoto JB, Senter PD. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Biol Med Chem Lett 2007;17:2278–80.

40. Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, et al. Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications. Bioanalysis 2013;5:1073–81.

41. De Groot FMH, Beusker PH, Scheeren JW, de Vos D, van Berkom LWA, Busscher GF, et al. Elongated and multiple spacers in activatable prodrugs. Int Patent Publ WO02/083180.
# Molecular Cancer Therapeutics

## Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim Dokter, Ruud Ubink, Miranda van der Lee, et al.

*Mol Cancer Ther* 2014;13:2618-2629. Published OnlineFirst September 4, 2014.

| Updated version | Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-14-0040-T |
|-----------------|-------------------------------------------------------------------------------------------------|
| Supplementary Material | Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2014/09/05/1535-7163.MCT-14-0040-T.DC1 |

| Cited articles | This article cites 37 articles, 13 of which you can access for free at: http://mct.aacrjournals.org/content/13/11/2618.full#ref-list-1 |
|----------------|----------------------------------------------------------------------------------------------------------------------------------|
| Citing articles | This article has been cited by 13 HighWire-hosted articles. Access the articles at: http://mct.aacrjournals.org/content/13/11/2618.full#related-urls |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
|---------------|------------------------------------------------------------------------|
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/13/11/2618. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |